Literature DB >> 2054275

Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies.

Y Zhang1, R A Blouin, P J McNamara, J Steinmetz, P J Wedlund.   

Abstract

The reproducibility of the S-/R-mephenytoin ratio was examined in urines stored at -20 degrees C over 2 years. Large changes in this ratio were observed in some urine samples stored for only a few months under these conditions. The changes observed in the S-/R-mephenytoin ratio are attributed to the decomposition of an acid labile metabolite of S-mephenytoin which is eliminated in the urine. The instability of this metabolite makes it desirable to process urine shortly after its collection in order to avoid inaccurate phenotype assignments based upon the urinary S-/R-mephenytoin ratio. If rapid processing of urines is impractical, additional methods are described for preventing improper phenotype assignment of subjects.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2054275      PMCID： PMC1368365          DOI： 10.1111/j.1365-2125.1991.tb05542.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man.

Authors:  P J Wedlund; B J Sweetman; G R Wilkinson; R A Branch
Journal:  Drug Metab Dispos       Date:  1987 Mar-Apr       Impact factor: 3.922

2.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

3.  Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo.

Authors:  U T Meier; P Dayer; P J Malè; T Kronbach; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

4.  S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.

Authors:  E J Sanz; T Villén; C Alm; L Bertilsson
Journal:  Clin Pharmacol Ther       Date:  1989-05       Impact factor: 6.875

5.  Mephenytoin hydroxylation deficiency: kinetics after repeated doses.

Authors:  A Küpfer; P Desmond; R Patwardhan; S Schenker; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-01       Impact factor: 6.875

6.  Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.

Authors:  A Drøhse; L Bathum; K Brøsen; L F Gram
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

7.  Rapid screening for polymorphisms in dextromethorphan and mephenytoin metabolism.

Authors:  R J Guttendorf; M Britto; R A Blouin; T S Foster; W John; K A Pittman; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

8.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects.

Authors:  P J Wedlund; W S Aslanian; E Jacqz; C B McAllister; R A Branch; G R Wilkinson
Journal:  J Pharmacol Exp Ther       Date:  1985-09       Impact factor: 4.030

9.  Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.

Authors:  P J Wedlund; W S Aslanian; C B McAllister; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875
  9 in total
  8 in total

1.  Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.

Authors:  L Bathum; E Skjelbo; T K Mutabingwa; H Madsen; M Hørder; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

2.  Interphenotype differences in disposition and effect on gastrin levels of omeprazole--suitability of omeprazole as a probe for CYP2C19.

Authors:  M Chang; G Tybring; M L Dahl; E Götharson; M Sagar; R Seensalu; L Bertilsson
Journal:  Br J Clin Pharmacol       Date:  1995-05       Impact factor: 4.335

3.  Mephenytoin as a probe for CYP2C19 phenotyping:effect of sample storage, intra-individual reproducibility and occurrence of adverse events.

Authors:  W J Tamminga; J Wemer; B Oosterhuis; J Wieling; D J Touw; R A de Zeeuw; L F de Leij; J H Jonkman
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 4.  Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

Authors:  D A Flockhart
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

5.  Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.

Authors:  K Brøsen; E Skjelbo; H Flachs
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

6.  Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.

Authors:  K Weerasuriya; R L Jayakody; C A Smith; C R Wolf; G T Tucker; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

7.  Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity.

Authors:  Tobias Klaassen; Alexander Jetter; Dorota Tomalik-Scharte; Dirk Kasel; Julia Kirchheiner; Ulrich Jaehde; Uwe Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-12-11       Impact factor: 2.953

8.  The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.

Authors:  E Skjelbo; L F Gram; K Brøsen
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.